EUVIMEDEUVIMED entdecken
Crossref

Real world evidence of sacituzumab govitecan in unresectable or metastatic triple negative breast cancer

Mohamed Sheeraz Mohamed Azhar, Oghenevwede Okuma, Yetunde Owoseni, Oyeyemi Akala, Rabia Gul, Husam Yassin, Olubukola Ayodele

Clinical Oncology · 2026-03 · 51 · 104018

DOI: 10.1016/j.clon.2025.104018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Oncology, 2026-03. Verfasst von Mohamed Sheeraz Mohamed Azhar und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Azhar, M. S. M., Okuma, O., Owoseni, Y., Akala, O., Gul, R., Yassin, H., & Ayodele, O. (2026). Real world evidence of sacituzumab govitecan in unresectable or metastatic triple negative breast cancer. Clinical Oncology, 51, 104018. https://doi.org/10.1016/j.clon.2025.104018

Vancouver

Azhar MSM, Okuma O, Owoseni Y, Akala O, Gul R, Yassin H, et al. Real world evidence of sacituzumab govitecan in unresectable or metastatic triple negative breast cancer. Clinical Oncology. 2026;51:104018. doi:10.1016/j.clon.2025.104018

BibTeX
@article{Azhar2026,
  author = {Azhar, Mohamed Sheeraz Mohamed and Okuma, Oghenevwede and Owoseni, Yetunde and Akala, Oyeyemi and Gul, Rabia and Yassin, Husam and Ayodele, Olubukola},
  title = {Real world evidence of sacituzumab govitecan in unresectable or metastatic triple negative breast cancer},
  journal = {Clinical Oncology},
  year = {2026},
  volume = {51},
  pages = {104018},
  doi = {10.1016/j.clon.2025.104018}
}
Kostenlos starten →